PH 797804

Drug Profile

PH 797804

Alternative Names: PH-797804

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antirheumatics; Benzamides; Pyrones; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Musculoskeletal pain; Neuropathic pain; Rheumatoid arthritis

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 07 Aug 2014 Discontinued - Phase-II for Chronic obstructive pulmonary disease (Combination therapy) in Argentina (PO)
  • 07 Aug 2014 Discontinued - Phase-II for Chronic obstructive pulmonary disease (Combination therapy) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top